PMID- 34521726
OWN - NLM
STAT- MEDLINE
DCOM- 20230626
LR  - 20230821
IS  - 2047-9956 (Print)
IS  - 2047-9964 (Electronic)
IS  - 2047-9956 (Linking)
VI  - 30
IP  - 4
DP  - 2023 Jul
TI  - Switching of monoclonal antibodies against calcitonin gene-related peptide in 
      chronic migraine in clinical practice: a case series.
PG  - e19
LID - 10.1136/ejhpharm-2021-002946 [doi]
AB  - A multicentre case series of patients with chronic migraine (CM) treated with 
      monoclonal antibodies directed against calcitonin gene-related peptide 
      (CGRP-mAbs) switching were developed. The effectiveness and safety of CGRP-mAbs 
      switching as a preventive treatment for CM in clinical practice were recorded. 
      Effectiveness was measured by >/=50% reduction of monthly migraine days in respect 
      to baseline and reduction in pain intensity. Safety was analysed through adverse 
      events (AEs) and treatment discontinuations. Seven patients were included. The 
      reason for switching was non-response in all cases. Two patients presented a 
      response to the first CGRP-mAb, but the effect was lost after 3 months. The 
      remaining five patients were non-responders. Response to the second CGRP-mAb was 
      observed in three patients, one of them for >3 months. Less than half of the 
      patients previously treated with a CGRP-mAb responded to switching with a second 
      CGRP-mAb. AEs were rare, with no treatment discontinuations.
CI  - (c) European Association of Hospital Pharmacists 2023. No commercial re-use. See 
      rights and permissions. Published by BMJ.
FAU - Briceno-Casado, Maria Del Pilar
AU  - Briceno-Casado MDP
AUID- ORCID: 0000-0002-4251-2843
AD  - Pharmacy, Hospital General Nuestra Senora del Prado, Talavera de la Reina, 
      Castilla-La Mancha, Spain pilarbricenocasado@gmail.com.
FAU - Gil-Sierra, Manuel David
AU  - Gil-Sierra MD
AD  - Department of Pharmacology, Universidad de Sevilla, Sevilla, Spain.
AD  - Pharmacy, Hospital Doctor Jose Molina Orosa, Lanzarote, Las Palmas, Spain.
FAU - De-La-Calle-Riaguas, Beatriz
AU  - De-La-Calle-Riaguas B
AD  - Pharmacy, Hospital General Nuestra Senora del Prado, Talavera de la Reina, 
      Castilla-La Mancha, Spain.
LA  - eng
PT  - Journal Article
DEP - 20210914
PL  - England
TA  - Eur J Hosp Pharm
JT  - European journal of hospital pharmacy : science and practice
JID - 101578294
RN  - JHB2QIZ69Z (Calcitonin Gene-Related Peptide)
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Humans
MH  - *Calcitonin Gene-Related Peptide/therapeutic use
MH  - Antibodies, Monoclonal/adverse effects
MH  - *Migraine Disorders/drug therapy/prevention & control
PMC - PMC10359803
OTO - NOTNLM
OT  - drug substitution
OT  - neurology
OT  - pain management
OT  - quality of health care
OT  - safety
COIS- Competing interests: MDG-S: membership of an advisory board (consultation fees) 
      and lecture for Janssen Pharmaceutica (reimbursement for attending symposia) of 
      another cancer drug.
EDAT- 2021/09/16 06:00
MHDA- 2023/06/26 06:41
PMCR- 2024/07/01
CRDT- 2021/09/15 06:14
PHST- 2021/07/03 00:00 [received]
PHST- 2021/08/31 00:00 [accepted]
PHST- 2024/07/01 00:00 [pmc-release]
PHST- 2023/06/26 06:41 [medline]
PHST- 2021/09/16 06:00 [pubmed]
PHST- 2021/09/15 06:14 [entrez]
AID - ejhpharm-2021-002946 [pii]
AID - 10.1136/ejhpharm-2021-002946 [doi]
PST - ppublish
SO  - Eur J Hosp Pharm. 2023 Jul;30(4):e19. doi: 10.1136/ejhpharm-2021-002946. Epub 
      2021 Sep 14.